tiprankstipranks
Advertisement
Advertisement
AbbVie Targets Tough Pancreatic Cancer With New Phase 2/3 Telisotuzumab Study
PremiumCompany AnnouncementsAbbVie Targets Tough Pancreatic Cancer With New Phase 2/3 Telisotuzumab Study
8d ago
AbbVie presents new data on fixed-duration venetoclax-based combination at EHA
Premium
The Fly
AbbVie presents new data on fixed-duration venetoclax-based combination at EHA
8d ago
JEPI vs. JEPQ: Two Active Income ETFs with Over 20% Growth Potential
Premium
Market News
JEPI vs. JEPQ: Two Active Income ETFs with Over 20% Growth Potential
10d ago
AbbVie’s RINVOQ Safety Study In Japan: What The Latest Update Means For ABBV Investors
PremiumCompany AnnouncementsAbbVie’s RINVOQ Safety Study In Japan: What The Latest Update Means For ABBV Investors
17d ago
AbbVie Advances New Autoimmune Drug ABBV-519 Into First-in-Human Trial, Signaling Next Wave in Immunology
Premium
Company Announcements
AbbVie Advances New Autoimmune Drug ABBV-519 Into First-in-Human Trial, Signaling Next Wave in Immunology
22d ago
AbbVie announces EC authorizes expanded label for Venclyxto
Premium
The Fly
AbbVie announces EC authorizes expanded label for Venclyxto
22d ago
AbbVie’s Allergan Aesthetics receives positive CHMP opinion for Boey
PremiumThe FlyAbbVie’s Allergan Aesthetics receives positive CHMP opinion for Boey
30d ago
AbbVie’s NAAVIGATE Trial Targets One-Time Gene Therapy for Diabetic Retinopathy
Premium
Company Announcements
AbbVie’s NAAVIGATE Trial Targets One-Time Gene Therapy for Diabetic Retinopathy
1M ago
AbbVie Earnings Call Highlights Growth Amid Transition
Premium
Company Announcements
AbbVie Earnings Call Highlights Growth Amid Transition
1M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100